Emmanuel Gyan is an expert in Hematology at Centre Hospitalier Universitaire de Tours (France). As of September 2026, ScienceLeadR ranks Emmanuel Gyan in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Leukemia. Emmanuel Gyan has authored 405 publications, the most recent in 2026, and is an investigator in 66 clinical trials, 23 of them ongoing. SLR score: 1,700 (community average: 125). How the SLR is computed.

LeadR Profile

1 700 ScienceLeadR Reputation 1700
Network Map

Hematology

Subspecialties: Oncology - Immunology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

POSITION Since September 2014, I am professor in hematology at the Faculty of Medicine of Tours, France, and the head of department of the hematology and cell therapy unit. CLINICAL RESEARCH I am coordinator of several clinical studies at the national level, in the LYSA and the FILO collaborative groups: Identification of Trial ClincalTrials.gov Phase Role in Trial Year BRIEF protocol (LYSA) NCT01313611 II Coordinating investigator 2011-2012 FAMYLY protocol (GOELAMS) NCT01999413 II Coordinating investigator 2012-2014 R-NIMP Protocol (GOELAMS) NCT00842595 II Coordinating Investigator 2003-2008 At the hospital level, I am the medical coordinator of the clinical research platform, and responsible for the enhancement of early phase clinical research activity. In this perspective, together with the research administration of the university hospital, we have organized the phase I activity in à dedicated unit, and a study nurse on-duty list for week-end and night PK sampling. REGIONAL ORGANIZATION OF HEMATOLOGY Since my arrival un the Centre region in 2006, I have continued the work of my mentor Philippe Colombat, who created a regional network of physicians involved in hematology patient care. We organize two annual meetings and videoconferencing for difficult hematology cases. SUPPORTIVE CARE I have contributed to the creation of talking groups for children of patients fighting cancer. ONGOING PROJECT We are in the process of building an extension to the hematology department in order to be able to treat all the leukemias and allogeneic transplantations for patients of the region.

Organizations

Career arc: 2001 - 2026

Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 405

Citations

Citations: 10 374 1st author: 30 Last author: 31 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
[Launching the Association of Hematology Department Heads: Sharing experiences and supporting one another for better leadership].
PMID 42532708 — hematology, neoplasms
Bull Cancer20260
Hypnosis associated with local anesthesia versus local anesthesia alone during bone marrow biopsy: a randomized, controlled, multicenter study, QUALHYBOM.
PMID 42484702 — anesthesia, hypnosis, bone marrow, pain, biopsy, patient comfort, anesthesia, local, palliative care
Support Care Cancer20260
Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.
PMID 42459119 — thrombotic microangiopathies, cells, therapeutics, t-lymphocytes, car-t cell
Haematologica20260
[Attractiveness of the clinical hematology specialty in France: A cross-sectional perspective from medical students, residents, and practicing hematologists].
PMID 42309836 — hematology, neoplasms, career choice
Bull Cancer20260
CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.
PMID 42144288 — cells, hematology, lymphoma, central nervous system, therapeutics, nervous system, t-lymphocytes, car-t cell
Am J Hematol20260

Clinical Studies 66

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 19
Phase 3 17
N/A 13
Phase 1/Phase 2 8
Phase 1 6
Phase 2/Phase 3 3

By status:

Completed 23
Recruiting 16
Active not recruiting 15
Terminated 6
Unknown 5
Not yet recruiting 1

By type:

Interventional 59
Observational 7

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 8
multicentric5to9 3
multicentricup10 43

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

23 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
OASIS II A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00 — cells, lymphoma, lymphoma, mantle-cell
Phase 1/Phase 2Active not recruiting2022
A clinical trial of MK 1045 and rituximab in people with follicular lymphoma (MK 1045 007)
2025-522777-10-00 — lymphoma, follicular, lymphoma, respect, rituximab, physicians
Phase 2/Phase 3Recruiting2026
A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Patients with Relapsed Refractory Aggressive B Cell Non Hodgkin s Lymphoma
2024-516791-15-00 — cytokines, cells, hodgkin disease, lymphoma, oxaliplatin, cytokine release syndrome, lymphoma, non-hodgkin, b-lymphocytes
Phase 2Active not recruiting2025
1L LUSPA VS ESA IN NTD LOW RISK MDS PATIENTS
2022-500430-29-00 — epoetin alfa, myelodysplastic syndromes, safety, anemia, therapeutics, erythropoiesis
Phase 3Active not recruiting2023
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma
2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map